Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical Trials

    Summary
    EudraCT number
    2005-000051-15
    Trial protocol
    DE   CZ   IT   HU  
    Global end of trial date
    14 Aug 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    01 Aug 2024
    First version publication date
    01 Aug 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    A4061008
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00828919
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Pfizer Inc.
    Sponsor organisation address
    66 East Hudson boulevard, New York, United States, NY 1001
    Public contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Scientific contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Jan 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    14 Aug 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The objective of the trial was to provide continued access to axitinib tablets and to the study drugs given in combination (if applicable) to participants who had completed their participation in a prior axitinib monotherapy or combination study and who had documented stable disease, responding disease or clinical benefit at the time they discontinued from the previous trial.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    07 Mar 2003
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Czechia: 2
    Country: Number of subjects enrolled
    France: 5
    Country: Number of subjects enrolled
    Hungary: 1
    Country: Number of subjects enrolled
    Italy: 1
    Country: Number of subjects enrolled
    Japan: 7
    Country: Number of subjects enrolled
    Korea, Republic of: 1
    Country: Number of subjects enrolled
    Russian Federation: 1
    Country: Number of subjects enrolled
    Taiwan: 1
    Country: Number of subjects enrolled
    United States: 30
    Worldwide total number of subjects
    49
    EEA total number of subjects
    9
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    35
    From 65 to 84 years
    14
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    A total of 52 participants were enrolled in this study, out of which 49 participants were treated. 3 enrolled participants had unreported dosing information.

    Pre-assignment
    Screening details
    This study was conducted in participants with solid tumors who had completed their participation in prior axitinib monotherapy or combination therapy clinical trial and who had documented stable disease, responding disease or clinical benefit at the time of prior clinical trial closure. No participant enrolled in axitinib combination therapy group.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Axitinib Monotherapy
    Arm description
    Participants under current study (A4061008) received oral dose of Axitinib alone twice daily as they were taking in the previous clinical trial. Maximum treatment duration was of 119.56 months.
    Arm type
    Experimental

    Investigational medicinal product name
    Axitinib
    Investigational medicinal product code
    AG-013736
    Other name
    Inlyta
    Pharmaceutical forms
    Film-coated tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received oral dose of Axitinib, starting dose from 1 to 8 milligram twice a day

    Number of subjects in period 1
    Axitinib Monotherapy
    Started
    49
    Completed
    0
    Not completed
    49
         Adverse events
    10
         Death
    3
         No longer willing to participate in study
    2
         Insufficient Clinical Response
    3
         Unspecified
    2
         Alternative source of treatment
    1
         Lost to follow-up
    1
         Objective progression or relapse
    24
         Discontinued for reason other than adverse event
    3

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Axitinib Monotherapy
    Reporting group description
    Participants under current study (A4061008) received oral dose of Axitinib alone twice daily as they were taking in the previous clinical trial. Maximum treatment duration was of 119.56 months.

    Reporting group values
    Axitinib Monotherapy Total
    Number of subjects
    49 49
    Age categorical
    Units: Participants
        Adults (18-64 years)
    35 35
        From 65-84 years
    14 14
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    60.4 ( 9.0 ) -
    Sex: Female, Male
    Units: Participants
        Female
    14 14
        Male
    35 35
    Race (NIH/OMB)
    Units: Subjects
        Asian
    11 11
        Black or African American
    1 1
        White
    32 32
        Unknown or Not Reported
    5 5

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Axitinib Monotherapy
    Reporting group description
    Participants under current study (A4061008) received oral dose of Axitinib alone twice daily as they were taking in the previous clinical trial. Maximum treatment duration was of 119.56 months.

    Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs

    Close Top of page
    End point title
    Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment Related TEAEs and Treatment Related Serious TEAEs [1]
    End point description
    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of an AE to study drug was based on investigator's assessment. AEs included both serious and all non-serious AEs. Safety population included all participants who received at least 1 dose of Axitinib under A4061008 protocol.
    End point type
    Primary
    End point timeframe
    Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow up to approximately 120.56 months)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive analysis was planned for this primary endpoint.
    End point values
    Axitinib Monotherapy
    Number of subjects analysed
    49
    Units: Participants
        TEAEs
    49
        Serious TEAEs
    21
        Treatment Related TEAEs
    47
        Treatment Related Serious TEAEs
    15
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 up to 28 days after last dose of study drug (maximum treatment exposure was 119.56 months; maximum follow up to approximately 120.56 months)
    Adverse event reporting additional description
    Same event may appear as both non-SAE and SAE but what is presented are distinct events. An event may be categorised as serious in one participant and nonserious in another participant or one participant may have experienced both serious and non-serious event. Safety population was analysed.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Axitinib Monotherapy
    Reporting group description
    Participants under current study (A4061008) received oral dose of Axitinib alone twice daily as they were taking in the previous clinical trial. Maximum treatment duration was of 119.56 months.

    Serious adverse events
    Axitinib Monotherapy
    Total subjects affected by serious adverse events
         subjects affected / exposed
    21 / 49 (42.86%)
         number of deaths (all causes)
    5
         number of deaths resulting from adverse events
    2
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Lymphocytic leukaemia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Diffuse large B-cell lymphoma
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Hypotension
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Surgical and medical procedures
    Cholecystectomy
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chest pain
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Disease progression
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Respiratory, thoracic and mediastinal disorders
    Pneumothorax
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Pleural effusion
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pulmonary toxicity
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Confusional state
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Investigations
    Blood creatinine increased
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Cardio-respiratory arrest
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences causally related to treatment / all
    1 / 3
         deaths causally related to treatment / all
    1 / 2
    Acute coronary syndrome
         subjects affected / exposed
    2 / 49 (4.08%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Intracardiac thrombus
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences causally related to treatment / all
    5 / 6
         deaths causally related to treatment / all
    0 / 0
    Arrhythmia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Aphasia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Dizziness
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Posterior reversible encephalopathy syndrome
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Transient global amnesia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Retinal vein occlusion
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    2 / 49 (4.08%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ascites
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enterocolitis
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vomiting
         subjects affected / exposed
    2 / 49 (4.08%)
         occurrences causally related to treatment / all
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Nausea
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastric ulcer haemorrhage
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Biliary obstruction
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Proteinuria
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Septic shock
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences causally related to treatment / all
    1 / 7
         deaths causally related to treatment / all
    0 / 0
    Hyperkalaemia
         subjects affected / exposed
    2 / 49 (4.08%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 49 (2.04%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Axitinib Monotherapy
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    48 / 49 (97.96%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    28 / 49 (57.14%)
         occurrences all number
    36
    General disorders and administration site conditions
    Oedema
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    5
    Influenza like illness
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Fatigue
         subjects affected / exposed
    21 / 49 (42.86%)
         occurrences all number
    32
    Chills
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    4
    Chest pain
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    7
    Asthenia
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    5
    Pyrexia
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    6
    Oedema peripheral
         subjects affected / exposed
    7 / 49 (14.29%)
         occurrences all number
    8
    Reproductive system and breast disorders
    Erectile dysfunction
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    4
    Respiratory, thoracic and mediastinal disorders
    Dysphonia
         subjects affected / exposed
    9 / 49 (18.37%)
         occurrences all number
    10
    Cough
         subjects affected / exposed
    8 / 49 (16.33%)
         occurrences all number
    10
    Oropharyngeal pain
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Epistaxis
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    6
    Dyspnoea
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    8
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    5 / 49 (10.20%)
         occurrences all number
    10
    Investigations
    Blood cholesterol increased
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Weight decreased
         subjects affected / exposed
    17 / 49 (34.69%)
         occurrences all number
    28
    Blood creatinine increased
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Nervous system disorders
    Taste disorder
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    4
    Paraesthesia
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    4
    Headache
         subjects affected / exposed
    12 / 49 (24.49%)
         occurrences all number
    13
    Dizziness
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    7
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    4
    Anaemia
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    6
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    7
    Vomiting
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    17
    Stomatitis
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    10
    Nausea
         subjects affected / exposed
    11 / 49 (22.45%)
         occurrences all number
    28
    Gastrooesophageal reflux disease
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Dyspepsia
         subjects affected / exposed
    7 / 49 (14.29%)
         occurrences all number
    9
    Diarrhoea
         subjects affected / exposed
    30 / 49 (61.22%)
         occurrences all number
    63
    Constipation
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    8
    Abdominal pain upper
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    6
    Skin and subcutaneous tissue disorders
    Hyperkeratosis
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    8
    Dry skin
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    6
    Alopecia
         subjects affected / exposed
    5 / 49 (10.20%)
         occurrences all number
    5
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    19 / 49 (38.78%)
         occurrences all number
    31
    Rash
         subjects affected / exposed
    5 / 49 (10.20%)
         occurrences all number
    6
    Renal and urinary disorders
    Proteinuria
         subjects affected / exposed
    14 / 49 (28.57%)
         occurrences all number
    114
    Dysuria
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    4
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    16 / 49 (32.65%)
         occurrences all number
    17
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    9 / 49 (18.37%)
         occurrences all number
    13
    Myalgia
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    6
    Musculoskeletal stiffness
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    4
    Arthralgia
         subjects affected / exposed
    11 / 49 (22.45%)
         occurrences all number
    11
    Back pain
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    8
    Infections and infestations
    Tooth infection
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Sinusitis
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    7
    Rhinitis
         subjects affected / exposed
    5 / 49 (10.20%)
         occurrences all number
    5
    Nasopharyngitis
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Urinary tract infection
         subjects affected / exposed
    3 / 49 (6.12%)
         occurrences all number
    3
    Upper respiratory tract infection
         subjects affected / exposed
    9 / 49 (18.37%)
         occurrences all number
    19
    Metabolism and nutrition disorders
    Hyperuricaemia
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    5
    Hyperglycaemia
         subjects affected / exposed
    6 / 49 (12.24%)
         occurrences all number
    7
    Dehydration
         subjects affected / exposed
    4 / 49 (8.16%)
         occurrences all number
    4
    Decreased appetite
         subjects affected / exposed
    8 / 49 (16.33%)
         occurrences all number
    13

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    04 Nov 2004
    The drug formulations were updated to include a 1-mg and 5-mg tablet. The 10-mg tablet was no longer available. The adverse event reporting section (Section 8) was updated to reflect Pfizer’s current safety reporting procedures.
    17 Oct 2006
    Trail treatment section was updated. Safety assessment section was updated.
    06 Feb 2008
    Trail Design section was updated. Safety assessment section was updated.
    15 Dec 2008
    Trail Design section was updated. Safety assessment section was updated.
    05 Dec 2012
    Update of safety information to align with most recent version of Investigator Brochure (IB). Update AE and safety wording, including pregnancy and Hy’s law, to align with current Pfizer SOP (Standard Operating Procedures).

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 11:56:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA